Proapoptotic ginsenosides compound K and Rh enhance Fas-induced cell death of human astrocytoma cells through distinct apoptotic signaling pathways.
OBJECTIVE
Malignant astrocytomas are among the commonest primary brain tumors and they have a grave prognosis, and so there is an urgent need to develop effective treatment. In this study, we investigated the molecular mechanisms that are responsible for the anti-tumor effect of ginsenosides on human astrocytoma cells.


METHODS
We tested 13 different ginsenosides for their anti-tumor effect on human malignant astrocytoma cells in conjunction with Fas stimulation. In addition, the cell signaling pathways were explored by using pharmacological inhibitors and performing immunoblot analysis. DCF-DA staining and antioxidant experiments were performed to investigate the role of reactive oxygen species as one of the apoptosis-inducing mechanisms.


RESULTS
Among the 13 different ginsenoside metabolites, compound K and Rh(2) induced apoptotic cell death of the astrocytoma cells in a caspase- and p38 MAPK-dependent manner, yet the same treatment had no cytotoxic effect on the primary cultured human astrocytes. Combined treatment with ginsenosides and Fas ligand showed a synergistic cytotoxic effect, which was mediated by the reduction of intracellular reactive oxygen species.


CONCLUSIONS
These results suggest that ginsenoside metabolites in combination with Fas ligand may provide a new strategy to treat malignant astrocytomas, which are tumors that are quite resistant to conventional anti-cancer treatment.
Choi
Kyungsun
K
Laboratory of Computational Cell Biology, Department of Bio and Brain Engineering, KAIST, Daejeon, Korea.
Choi
Chulhee
C
Blood. 2003 Jul 1;102(1):336-43
12623840
Liver Int. 2005 Oct;25(5):1069-73
16162168
J Korean Med Sci. 2001 Dec;16 Suppl:S38-41
11748375
Free Radic Biol Med. 2003 Sep 15;35(6):648-61
12957657
Toxicol Sci. 2006 Jun;91(2):356-64
16547074
J Immunol. 1999 Feb 15;162(4):1889-95
9973455
Cell Biol Int. 2007 Sep;31(9):1027-35
17468017
Brain Res Brain Res Rev. 2004 Jan;44(1):65-81
14739003
Neurosci Lett. 2007 Jun 21;421(1):37-41
17548155
Cancer Lett. 2004 Mar 8;205(1):23-9
15036657
Mol Cell Biol. 2002 Feb;22(3):724-36
11784850
Biochem Int. 1992 Jul;27(3):501-10
1417886
Science. 1995 Mar 10;267(5203):1449-56
7533326
Mol Cancer Ther. 2007 Jul;6(7):1909-19
17620423
EMBO J. 1996 Jan 15;15(2):216-25
8617197
J Neurooncol. 2004 Mar-Apr;67(1-2):167-76
15072464
Science. 2006 Jun 30;312(5782):1882-3
16809515
Brain Res. 2007 Mar 9;1136(1):190-9
17239831
Mol Carcinog. 2004 Jan;39(1):1-9
14694442
EMBO J. 1998 Mar 16;17(6):1675-87
9501089
J Biol Chem. 2002 Jun 14;277(24):21446-52
11934900
Planta Med. 2006 Jun;72(7):627-33
16673329
Cancer Lett. 2007 Nov 8;257(1):79-86
17692455
Oncogene. 2007 May 14;26(22):3100-12
17496909